NFL Biosciences is launching its listing on Euronext Growth this morning with an associated fundraising of 5.26 ME that can be increased to 8 ME. The price range is between 3.40 and 4.60 euros, with the transaction closing on June 30.
The company is developing a “high potential” botanical drug candidate for smoking cessation ready to enter Phase II / III. This is what the company finances.
NFL Biosciences is thus clinically developing a botanical drug candidate (NFL-101) composed of natural proteins extracted from tobacco leaves, and devoid of nicotine, as a smoking cessation aid. NFL-101 has been the subject of preclinical studies and a Phase I which has shown a strong reduction in the urge to smoke, successful long-term quit attempts, or a sharp reduction in consumption. daily, and this without presenting any toxicity. NFL-101 is protected by two families of patents.
NFL-101 is derived from a subcutaneous desensitization treatment that had been developed by the Pasteur Institute against allergies in workers in tobacco factories. Used without prescription by a French doctor on more than 10,000 smokers, the Pasteur extract repositioned on smoking cessation had shown promising results which were supported by a retrospective study. NFL-101 is a standardized version for pharmaceutical use. It is given as two injections under the skin, given one week apart when trying to stop. Two catch-up injections are available at months three and six, concomitant with new attempts to stop.
